Latest Headlines

Latest Headlines

Medtronic reveals corporate shakeup pending close of Covidien deal

Days after Medtronic revealed plans to refinance its $42.9 billion acquisition of Covidien due to new tax rules cracking down on inversions, the company announced a corporate shakeup pending the deal's close.

Impax gets products, manufacturing with $700M deal for allergy-drug makers

Back in August, Impax Laboratories CEO Fred Wilkinson told investors on a conference call that the company was "well-positioned to execute on a number of transactions." And now, the company has pulled the trigger on one of those deals, spending $700 million on a pair of Pennsylvania drugmakers.

With Allergan buy, Actavis could achieve its branded-drug ambitions

As Big Pharma's big patent cliff took hold a few years ago, generics makers enjoyed the sales boost of one newly off-patent blockbuster after another. But savvy execs knew that the unprecedented party would end soon enough--and generics companies would be facing a sort of patent cliff of their own.

CEO's latest forecast: A 'vast value gap' between Allergan and Valeant

Allergan has been insisting for months that Valeant's buyout offer is "grossly inadequate" and "substantially undervalues" the company. Now that Valeant has upped its bid by $4.5 billion? Same deal, the Botox maker says, citing its own rosy earnings forecast.

Auxilium dumps QLT inversion deal for $2.6B Endo buyout

In September, Auxilium Pharmaceuticals' CEO Adrian Adams shrugged off a $2.2 billion acquisition offer from Dublin-based Endo International, saying he'd rather do a reverse merger with Canada's QLT. Endo upped its offer to $2.6 billion in cash and stock--enough to seal the deal, the company announced today.

Auxilium takes money, runs from inversion with $2.6B Endo deal

Endo found the magic number in its negotiations with Auxilium Pharmaceuticals, boosting its offer to $2.6 billion and finally convincing its target to abandon plans for a tax-saving deal.

Buzz: Unsated by its Durata deal, Actavis looks again to buy Allergan

Fresh off signing up to buy Durata Therapeutics for $675 million, Actavis is making another overture for the embattled Allergan, Reuters reports, potentially setting up a bidding war with the dogged Valeant Pharmaceuticals.

UPDATED: With Actavis poised to swoop in, Valeant eyes $4.5B hike in bid for Allergan

Valeant CEO J. Michael Pearson has said he's confident Allergan shareholders will vote in support of his company's hostile bid come December. But it never hurts to have a little insurance.

Med tech deal value up 363% in first half, with megadeals still pending

A recent report by Evaluate MedTech released at the annual AdvaMed med tech conference in Chicago found that M&A deal value in the med tech sector grew by 363% year over year in the first half of 2014 to $30 billion.

Allergan asks judge to nix Ackman's voting rights at special meeting

Allergan's still okay with holding a special shareholder meeting on Dec. 18, a date it last month agreed on with wannabe acquirer Valeant. It just doesn't want its pursuer's partner, Bill Ackman, to have a say.